Bipartisan House bill seeks to boost pediatric drug development via new FDA penalties for noncompliance

Lia DeGroot

A bipartisan duo of lawmakers is seeking to boost pediatric drug development with new legislation that would prioritize adding pediatric patients to trials for new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bipartisan House bill seeks to boost pediatric drug development via new FDA penalties for noncompliance

Lia DeGroot

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Edgewise’s stock surges as heart drug passes early safety test

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Stem cell startup spun out of George Church’s lab raises $75M

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Breaking down silos with a new quantitative approach to drug development

Bi­par­ti­san House bill seeks to boost pe­di­atric drug de­vel­op­ment via new FDA penal­ties for non­com­pli­ance

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bipartisan House bill seeks to boost pediatric drug development via new FDA penalties for noncompliance